Drug intelligence / Profile preview

j2h-2104

Development stage: Preclinical
Lead developer: J2H Biotech
Modality: Small Molecules

Overview

J2H-2104 is a small molecule drug developed by J2H Biotech, Inc. It is currently in preclinical development for the treatment of solid tumors and has also been considered for atopic dermatitis and osteoarthritis, though its primary focus appears to be oncology. The specific target or mechanism of action has not been publicly disclosed in detail; it is described as having a "novel target" in some sources[1][3][4]. The drug leverages J2H Biotech’s proprietary OPTIFLEX® platform for efficient discovery and optimization.

Beyond the preview

Go deeper on j2h-2104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on j2h-2104.

Explore the full profile